Plunksna ir trintukas - Company finances
|
EUR
|
2020
From: 2020-09-11
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | 3,075 | 15,648 | 15,095 | 13,690 | 13,290 | 14,025 |
| Profit before tax | 167 | 1,912 | 2,969 | 301 | -1,193 | 1,151 |
| Net profit | 167 | 1,912 | 2,969 | 254 | -1,193 | 999 |
| Equity | 367 | 2,042 | 5,011 | 5,265 | 4,073 | 5,071 |
| Liabilities | - | - | 0 | 85 | -283 | 152 |
| Non-current assets | 0 | 0 | 0 | 0 | 3,790 | 0 |
| Current assets | 367 | 2,042 | 5,011 | 5,350 | 0 | 5,223 |
| Total assets | 367 | 2,042 | 5,011 | 5,350 | 3,790 | 5,223 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | 830 | 695 | 449 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | +408.9% | -3.5% | -9.3% | -2.9% | +5.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 45.5% | 93.6% | 59.2% | 4.7% | -31.5% | 19.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 45.5% | 93.6% | 59.2% | 4.8% | -29.3% | 19.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.4% | 12.2% | 19.7% | 1.9% | -9.0% | 7.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.4% | 12.2% | 19.7% | 2.2% | -9.0% | 8.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 0.0 | - | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Plunksna ir trintukas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-09-05 | 2026-09-10 | 275.97 |
| 2026-09-01 | 2026-09-02 | 275.97 |
| 2026-08-26 | 2026-08-31 | 195.49 |
| 2026-08-23 | 2026-08-23 | 195.49 |
| 2026-08-19 | 2026-08-19 | 195.49 |
| 2026-08-16 | 2026-08-17 | 195.49 |
| 2026-08-01 | 2026-08-14 | 195.49 |
| 2026-07-01 | 2026-07-31 | 115.01 |
| 2026-06-15 | 2026-06-30 | 34.53 |
| 2026-06-12 | 2026-06-14 | 275.27 |
| 2026-06-02 | 2026-06-11 | 80.48 |
| 2023-07-19 | 2023-07-31 | 1066.17 |
Plunksna ir trintukas - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Plunksna ir trintukas, MB (code 305622361) is a small partnership active in research and development in medical sciences. In 2025, it generated revenue of €14.0K, slightly above the €13.3K recorded in 2024 and broadly in line with the €13.7K achieved in 2023. Profitability improved strongly after a loss in 2024: net profit was €999 in 2025, compared with -€1.2K in 2024 and €254 in 2023. The 2025 profit margin reached 7.1%, indicating a return to positive operating performance. The balance sheet remained small, with total assets of €5.2K and equity of €5.1K at the end of 2025, while liabilities were only €152. This resulted in a very strong equity ratio of 97.1% and a low debt-to-equity ratio of 0.03. Efficiency ratios were also solid, with ROE at 19.7%, ROA at 19.1%, and asset turnover at 2.69x. Overall, the 2025 figures show a modest but profitable business with stable revenue and a markedly improved bottom line.